Therapeutic use of tea derivatives: all that glitters is not gold.

摘要

In 2 interesting articles published in the June 4, 2009 issue of Blood, attention was focused on the possibility for green tea derivatives to inhibit the therapeutic activity of bortezomib, an anticancer agent very effective in multiple myeloma and mantle cell lymphoma.1'2 However, the interaction with boronic acid-based proteasome inhibitors is not the only important interaction between green tea and drugs. In fact, both green tea and black tea derivatives have been shown to modulate the activity of several drug metabolizing enzymes, and this effect could be responsible for undesired variations in plasma concentration of many drugs.